YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a…
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new r…
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option progra…
This article first appeared on GuruFocus. Global Leqembi Sales (Q2 2026): JPY29.3 billion (~$184 million), a 12% increase from Q1 2026 and a 27% increase from Q2 2025. Royalties (Q2 2026): Increased 12% to SEK179.4 million. Excluding a one…
Eli Lilly (NYSE:LLY) agreed a new research and collaboration deal with BioArctic that applies BioArctic's BrainTransporter technology to a potential Alzheimer's treatment. The BioArctic agreement expands Eli Lilly's drug development activi…
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to M…
STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, n…
STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeuticsannounced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach…
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's seco…
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients w…
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a o…
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating…
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC…
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new trea…
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119…
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million f…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration th…
STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment…
The European market has shown resilience with the pan-European STOXX Europe 600 Index edging up slightly, as investors remain hopeful for geopolitical resolutions that could stabilize energy markets and boost economic confidence. In this e…
As European markets navigate the complexities of geopolitical developments and economic fluctuations, investors are keenly observing growth opportunities amid a backdrop of cautious optimism. In this environment, stocks with high insider o…
STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program res…
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet…
The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 3.00% amid hopes for de-escalation in the Middle East, although economic growth forecasts have been tempered due to energy shocks and geopolit…
As the European market experiences a positive shift with the STOXX Europe 600 Index rising by 3.00%, driven by optimism around geopolitical tensions easing in the Middle East, investors are keenly observing high-growth opportunities within…
As European markets experience a positive shift, driven by hopes of geopolitical de-escalation and rising indices such as Germany's DAX and France's CAC 40, investors are increasingly focusing on growth companies with substantial insider o…
Amid a backdrop of rising hopes for geopolitical stability and modest growth in the European market, the pan-European STOXX Europe 600 Index has shown resilience with a 3.00% weekly increase. In this environment, identifying high-growth te…
As European markets experience a positive upswing, with the STOXX Europe 600 Index climbing 3.00% amid hopes for geopolitical de-escalation, investors are keenly observing growth opportunities despite the European Commission's downgraded e…
In May 2026, European markets have shown resilience with the pan-European STOXX Europe 600 Index rising by 3.00%, driven by optimism surrounding potential de-escalation in the Middle East. Despite a reduction in growth forecasts due to ene…
As European markets experience an upswing, with the pan-European STOXX Europe 600 Index rising by 3% amid hopes for geopolitical de-escalation, investors are keenly observing companies that exhibit both growth potential and significant ins…
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi…
As European markets experience a positive shift, with the STOXX Europe 600 Index gaining 3.00% amid hopes of geopolitical de-escalation, investors are increasingly focused on growth opportunities within the region. In this context, compani…
The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index ending the week down amid geopolitical tensions and rising energy costs that could lead to inflationary pressures. Despite these headwinds, rob…
This article first appeared on GuruFocus. Release Date: May 20, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BioArctic AB (BRCTF) reported strong financial result…
STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 20…
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, B…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The U.S. FDA’s three month extension of its review for Leqembi Iqli…